Laplace wins FDA IDE approval for TRIUMPH tricuspid valve trial

The pivotal study will evaluate Laplace’s TTVR system in severe tricuspid regurgitation, targeting about 400 randomized patients and a 150-patient registry across as many as 75 sites.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.